# Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event

> **NCT02877615** · PHASE2 · COMPLETED · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 585 (actual)

## Conditions studied

- Post Stroke Recovery

## Interventions

- **DRUG:** S 44819 150 mg twice a day
- **DRUG:** S 44819 300 mg twice a day
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02877615
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-19
- **Primary completion:** 2019-03-10
- **Final completion:** 2019-03-10
- **Target enrollment:** 585 (ACTUAL)
- **Last updated:** 2020-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02877615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02877615, "Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02877615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*